

Isaac Ciechanover, Atara Biotherapeutics Inc: Profile & Biography - Bloomberg


































































  






























Feedback





Isaac Ciechanover

Chairman/Pres/CEO/Co-Founder,
Atara Biotherapeutics Inc






Career History




President
Pinta Biotherapeutics  Inc, PRESENT


Chairman/Pres/CEO/Co-Founder
Atara Biotherapeutics Inc, PRESENT


President/CEO/Co-Founder
Atara Biotherapeutics Inc, 8/2012-UNKNOWN


Partner
Kleiner Perkins Caufield & Byers LLC, 5/2010-UNKNOWN


Exec Dir:Business Dev
Celgene Corp, FORMER


Head:Global Teams
Array Biopharma Inc, FORMER


Head:Global Teams
Agios Pharmaceuticals Inc, FORMER


Head:Global Teams
Merck Kgaa, FORMER


Show More









Website:
www.atarabio.com






Corporate Information
Address:

611 Gateway Blvd
Suite 900
S San Francisco, CA 94080
United States


Phone:
1-650-278-8930


Fax:
-


Web url:
www.atarabio.com











From The Web












Personal Information



Education



Harvard Business School
MBA


Weill Cornell Medical College
MD


University of Cambridge
Master's Degree


Stanford University
Bachelor's Degree, Physiology


Show More








Memberships



Board Memberships




Atara Biotherapeutics Inc


Chairman, PRESENT




Atara Biotherapeutics Inc


Board Member, 8/2012-UNKNOWN









Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data



































Isaac E Ciechanover - New York, NY | Intelius



























Sign In



We found Isaac E Ciechanover in New York, NY


Isaac E Ciechanover

                                                                           Intelius found that Isaac E Ciechanover  is  a male between 40 and 50 years old from New York, NY.  We have connected them to
                8 addresses,
                6 phones,
                and 6 relatives or associates.
         






Get Report Now

Age

Isaac E Ciechanover is in his 40s

Isaac Has Lived In

New York, NY
Palo Alto, CA
Santa Cruz, CA

Isaac's Relatives

Allison Ciechanover
Atara Ciechanover
Dasna Ciechanover
Tamar Ciechanover







Isaac E Ciechanover



Zodiac SignPisces



GenderMale



Professional Status
Executive Director In the Business Development at Kleiner Perkins Caufield & Byers



Get Report Now










Want to know more about Isaac? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Isaac, or use our people search engine to find others.
Get Background Check on Isaac E Ciechanover
Get a Criminal Check on Isaac E Ciechanover
Get a Public Record Report on Isaac E Ciechanover
Get a People Search Report on Isaac E Ciechanover


Isaac E Ciechanover's Contact Information
Known Cities Lived In
Find out where Isaac E Ciechanover has lived as well as Isaac E Ciechanover's phone numbers and email addresses.




Isaac E Ciechanover Has Lived in 2 States
New York Address for Isaac E Ciechanover


115 C****** A** 

New York, NY


Has Lived In

New York, NY
Palo Alto, CA


Get Full Address Report










Phone Numbers Associated with Isaac E Ciechanover

(415) ***-**** - Brisbane, CA 
(415) ***-**** - Brisbane, CA 
() ***-**** - New York, NY 


Get Full Phone Report



Email Addresses Associated with Isaac E Ciechanover

i**********r@***.com
i**************r@***.com
i**********r@***.com


Get Email Report




Isaac E Ciechanover's Professional Information
Information regarding Isaac E Ciechanover's professional history.  Find out previous places Isaac E Ciechanover has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Isaac E Ciechanover Has Worked at 4 Places
Company: Kleiner Perkins Caufield & Byers
               Title: Executive Director In the Business Development
Company: Atara Biotherapeutics, Inc.
               Title: President and Chief Executive Officer
Isaac E Ciechanover's Experience
Title: Executive Director In the Business Development
               Company: Kleiner Perkins Caufield & Byers
Job Details
               Company Size: $10 mil to less than $25 mil - Employee Range: 100 to less than 500
Title: President and Chief Executive Officer
               Company: Atara Biotherapeutics, Inc.
Job Details
               Company Size: $5 mil to less than $10 mil - Employee Range: Less than 25. Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation. Atara Bios programs include molecularly targeted product candidates and T-cell product candidates. Molecularly targeted product candidates include PINTA 745, STM 434 and ATA 842. These product candidates target myostatin and activin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications. T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL.
Additional Professional Information on Isaac E Ciechanover

 See Isaac E Ciechanover's LinkedIn Profile



Isaac E Ciechanover's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Isaac E Ciechanover


Isaac E Ciechanover's known Social Networks And Potential Email Matches

Find all of Isaac E Ciechanover's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Isaac Ciechanover
Username Matches

                  IsaacCiechanover
                  CiechanoverIsaac
                  Isaac.Ciechanover
                  Ciechanover.Isaac
                  Isaac_Ciechanover
                  Ciechanover_Isaac
                  Isaac-Ciechanover
                  Ciechanover-Isaac
                  ICiechanover
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
I Ciechanover







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.





















Ciechanover Isaac E. - Insider Stock Trading - OpenInsider











Sector

All Sectors

Group by Sector


Aerospace
Agriculture
Automobile
Building
Business Services
Chemical
Electrical
Energy
Fashion
Financial
Food & Beverage
Fund
Healthcare
Household
Insurance
Machinery
Media
Metals
Mining
Other
Personal Services
Real Estate
Retail
Technology
Telecom
Transportation
Utility




Industry

All Industries

Group by Industry






Insiders
Filings


All
Purchases
Sales

CIK: 1612096 - Address: 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080 53 results 

						Links
						


SECYahooGoogleFinvizTradingViewStockChartsStockTwitsDownload CSV 













TC
Stat
Stk
Ins
Fil
+d
+w
+m
+q
+h
+y
avg


S%ret1141-1-2-5-12-25-46-15S%wins596365698310073 




Filing Date
T Date
Ticker
IssuerInc Sector
IndIndustry
Owner
oSt
Rel
Title
T
TVal
Price
L
Qty
oc
Own
H
r2y
r1y
r6m
r3m
r6w
r3w
r7d
r3d
f1d
f1w
f1m
f3m
f6m
f1y



7/26/17 16:527/24/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-9116.490-601,182I
5/31/17 19:445/30/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-9213.350-7-11,188I
5/19/17 16:055/17/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-7214.915-501,195I-600-271-26-4-34
5/17/17 16:595/15/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOM.d00.005601,200D-600-271-26-4-34
4/26/17 19:344/25/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-12617.566-7-11,194I-71-151828-13-121-7-3-7
4/12/17 16:204/10/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-12317.036-7-11,201I-64-16-823-21-17-8-16-13
3/28/17 20:133/27/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-32120.067-16-11,208I-422014135219-539-3
3/20/17 18:503/16/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-59719.386-31-21,224I-3728528412416-1-5-3-15
2/16/17 20:082/15/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOM.d00.003601,255M-15-8-28-23218770-528
2/16/17 20:082/15/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.dm-7515.563-501,255M-15-8-28-23218770-528
2/6/17 17:292/2/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-6613.663-501,089I-32-25-431-8-4160013-1
1/19/17 16:341/17/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-8514.243-6-11,094I-42-20-31-9-24-3-13-3-101030
1/9/17 16:171/5/17ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-14216.894-8-11,100I-35-24-27-5-14611111-10-84
12/23/16 18:5212/22/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-7315.225-501,108I-47-40-32-28-25-23-20-13-3-10-1133
12/8/16 17:1612/6/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-12917.935-7-11,113I-43-50-14-1924-6-13-82-5-125
11/23/16 20:1311/22/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-22018.344-12-11,120I-32-482-91230-9022-27-31
11/17/16 16:5411/15/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOM.d00.004611,132D-31-4113-1953611-8-26-12-15
10/28/16 20:3710/26/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-6613.813-501,126I-33-49-24-43-30-21-14-6-6546-724
10/17/16 16:2710/13/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-7715.963-501,131I-45-24-26-19-20-13-11-2-829-1313
9/29/16 16:269/27/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-25020.873-12-11,543M-3415-3-221484-10-32-27-2
9/19/16 17:139/15/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-13919.363-7-1828I-6114-3-22-3-9-865-16-1711
8/23/16 19:578/22/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-21422.334-10-1835I-4651301-582-9-11-8-18-32
8/17/16 19:438/15/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOM.d00.00461845M-552840-3-7-10620-14-7-28
7/21/16 21:387/20/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-21222.117-10-11,170I-631066-2-30182-29-37
7/11/16 16:427/7/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-22022.887-10-11,179I-57512331753-1-3-1-22-25
6/27/16 16:576/23/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-20421.266-10-11,189I-59-11264011707910-3-29
6/8/16 20:196/7/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-24620.533-12-11,198I-53-452710312110-3-6112-6
5/27/16 18:385/25/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-12717.693-7-11,210I-56-531-18158-134191211
5/18/16 19:025/16/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOM.d00.004601,218D-60-51-8-30-1465010273727
4/26/16 21:174/25/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-2620.125-101,212I-66-165164-20-2-5-519-20
4/13/16 19:494/11/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-26920.405-13-11,213I-58-37314112-10-3-267-13
4/4/16 16:483/31/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-2420.035-101,226I-50-37-21212094-40-1490-1
2/18/16 20:122/16/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOM.d00.004601,227D-7-65-47-30-62253-5-20360
1/15/16 16:061/13/16ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-4820.2010-201,057I-18-64-25-41-9-1212-12-10-2425-28
1/4/16 16:1112/30/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-6226.0014-201,060I-1-42-12-18-2110164-8-23-13-5-37
12/16/15 17:1012/14/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-5422.4613-201,062I0-60-50-23-39-42-33-31-11-34-12-34
12/7/15 17:1512/3/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-15037.4510-401,065I22-14-95918522-2-26-45-34-38
11/25/15 16:0411/23/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-16835.0310-501,069I36-8-7261412153-3-40-58-57-52
11/18/15 18:5211/16/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOM.d00.0010611,073D17-21-34-1417-71015-30-50-51-44
10/23/15 19:2610/21/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-8325.8514-301,068I79-59-56-48-29-22-18-1639-19-15-38
10/8/15 16:2110/6/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-13233.0815-401,071I-23-32-8-26261-8-3-27-31-40
9/25/15 18:499/23/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-22442.9913-501,075I25-17-92-4-5-12-24-37-37-53-46
9/14/15 18:599/10/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-24046.1610-501,488M51-1-161321829-24-23-57-49
8/31/15 18:528/27/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-20439.2511-501,085I96-1-29-20-151-44-18-2-57-52
8/19/15 20:258/17/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOM.d00.0014611,090D147301-16-44-9-144-32-63-50
8/3/15 17:167/30/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-29256.1825-501,084I130394-9-6-60-9-29-56-67-58
7/20/15 20:307/16/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-31660.7127-501,090I14315331423-56-1-10-45-59-58
7/2/15 18:166/30/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-26250.4218-501,095I6613153-16-1441723-31-45-51
6/19/15 19:256/17/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-28554.7212-501,100I11646432419-60-34-9-58-65
6/8/15 18:426/4/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-27542.918-6-11,105I4860-2421149-174-5-18-56
5/26/15 19:235/21/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-15037.569-401,112M4065-21-8-2-136419-17-56
5/19/15 18:505/15/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOM.d00.00113231,116D72109-7-1683414531-13-56
4/24/15 16:154/22/15ATRAAtara Biotherapeutics, Inc.DEHealthBioPrdBiological Products, (No DiagCiechanover Isaac E.CADOCEOS.m-31961.368-501,099I36217193483419-19-29-35-1-54-61



DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing



S - SaleSale of securities on an exchange or to another person

S - Sale+OESale of securities on an exchange or to another person (after option exercise)

F - TaxPayment of exercise price or tax liability using portion of securities received from the company

P - PurchasePurchase of securities on an exchange or from another person


Return to top
Contact
Copyright © 2017 OpenInsider.com. All rights reserved.













Isaac E. Ciechanover M.D. - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Isaac E. Ciechanover M.D.
President, Chief Executive Officer and Chairman of the Board at Atara Biotherapeutics, Inc.


View Full Profile
Are you Isaac E. Ciechanover M.D.? Claim your profile


 


Sign up for Equilar Atlas and view Isaac E. Ciechanover M.D.'s full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Isaac E. Ciechanover M.D.'s  network and community.
												FOLLOW changes in Isaac E. Ciechanover M.D.'s employment and money-in-motion.
												CONNECT with Isaac E. Ciechanover M.D. through your network of contacts.
												








Isaac E. Ciechanover M.D.'s Executive Work History


Current


President, Chief Executive Officer and Chairman of the Board, 
Atara Biotherapeutics, Inc.


Past
To view Isaac E. Ciechanover M.D.'s complete executive work history, sign up now
Age
46

 
 


Isaac E. Ciechanover M.D.'s Biography



Isaac E. Ciechanover, M.D., 46, has served as our President and Chief Executive Officer and a member of the Board since our founding in August 2012. From April 2010 to November 2012, Dr. Ciechanover was a partner at Kleiner Perkins Caufield & Byers, a venture capital firm, where he primarily focused on life sciences investing. From 2004 to March 2010, he served in various capacities at Celgene Corporation, a biopharmaceutical company, most recently as Executive Director for Business Development. Dr. Ciechanover has also held business development and venture capital roles at pharmaceutical companies Amylin Pharmaceuticals and Pfizer and ventur ...
(Read More)

			Isaac E. Ciechanover, M.D., 46, has served as our President and Chief Executive Officer and a member of the Board since our founding in August 2012. From April 2010 to November 2012, Dr. Ciechanover was a partner at Kleiner Perkins Caufield & Byers, a venture capital firm, where he primarily focused on life sciences investing. From 2004 to March 2010, he served in various capacities at Celgene Corporation, a biopharmaceutical company, most recently as Executive Director for Business Development. Dr. Ciechanover has also held business development and venture capital roles at pharmaceutical companies Amylin Pharmaceuticals and Pfizer and venture capital firm Pequot Ventures. Dr. Ciechanover received a B.A. from Stanford University, an M.Phil. in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical College and an M.B.A. from Harvard Business School. We believe that Dr. Ciechanover's extensive experience in the life sciences industry and in business development, his role as our President and Chief Executive Officer, and his training as a physician, provide him with the qualifications and skills to serve on our Board.
		
Source: Atara Biotherapeutics, Inc. on 04/25/2017
		
	

 






Sign up for Equilar Atlas and view Isaac E. Ciechanover M.D.'s full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Isaac E. Ciechanover M.D.. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Isaac E. Ciechanover M.D.'s  network and community.
												FOLLOW changes in Isaac E. Ciechanover M.D.'s employment and money-in-motion.
												CONNECT with Isaac E. Ciechanover M.D. through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Isaac E. Ciechanover M.D.


















Isaac E. Ciechanover M.D.'s Connections (16)





Sign up now to view Isaac E. Ciechanover M.D.'s 16 connections »









Eric L. Dobmeier
Chief Operating Officer, Seattle Genetics, Inc.









Joseph S. Lacob
Board Member, Align Technology, Inc.









Margaret C. Whitman
Dir., President and Chief Executive Officer, Hewlett Packard Enterprise Company









Eckard Weber
Chairman of the Board, Ocera Therapeutics, Inc.









Joel S. Marcus
Chairman of the Board, Chief Executive Officer, President and Founder, Alexandria Real Estate Equities









Gad Soffer
Executive Vice President and Chief Strategy Officer, Atara Biotherapeutics, Inc.









Mitchall G. Clark
Chief Regulatory and Quality Assurance Officer, Atara Biotherapeutics, Inc.









Christopher Haqq
Executive Vice President, Research and Development and Chief Scientific Officer, Atara Biotherapeutics, Inc.









Matthew K. Fust
Board Member, Atara Biotherapeutics, Inc.









Carol G. Gallagher
Lead Independent Director, Atara Biotherapeutics, Inc.








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

� 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993













﻿







Isaac Ciechanover Sold 5,200 Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) – Octafinance
























































 








Friday, 28 July 2017

























 

Menu



Featured News


						2 years ago - Alphabet Inc (NASDAQ:GOOGL) Tests Its Ad Technology On Billboards To Cushion Itself Against Ad Blocks


						2 years ago - China Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking Crisis


						2 years ago - Marc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and Gold


						2 years ago - Carl Icahn Criticizes the Fed. Feels Bad For Investors Buying Junk Bonds


						2 years ago - John Burbank: European QE Can’t Save The Markets Same As the U.S. Quantitative Easing. Everything Will Be Liquidated










Isaac Ciechanover Sold 5,200 Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA)


08/03/2015  by OctaStaff 
			in Insider News, Momentum Equities 












Share with your friendsYour NameYour EmailRecipient EmailEnter a MessageI read this article and found it very interesting, thought it might be interesting for you. The article is called Isaac Ciechanover Sold 5,200 Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) and is was published by Octafinance.com at http://www.octafinance.com/isaac-ciechanover-sold-5200-shares-of-atara-biotherapeutics-inc-nasdaqatra/128943/.CaptchaSubmit
Isaac Ciechanover Insider Sell Transaction
 The Chief Executive Officer of Atara Biotherapeutics Inc (NASDAQ:ATRA)  15.20 -0.25 -1.62%, Isaac Ciechanover has made a surprising deal in the firm that is having a total value $292,160 U.S. Dollars. As announced in the Washington-based Security and Exchange Commission electronic document filed on August 03, 2015, Isaac sold 5,200 shares at average stock price per share of $56.2. It seems he is very active lately as in the last 30 days, he quietly sold additional 5,200 shares of the company, worth $315,680 USD. Isaac Ciechanover now has ownership of 1.08 million shares which are equivalent to exactly 4.38% of the California-based company’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding). 
Atara Biotherapeutics Inc Stock Rating, Sentiment and Fundamentals
 Three of the big league analysts responsible to analyzing the company’s share, predict an earnings-per-share of $-1.96 and a Price to Earnings ratio of NaN for the reporting year 2015.






Rating & SentimentPsychSignal Social:SELLAnalysts Rating:BUYHedge Funds Sentiment:BUY




Stock FundamentalsEarnings + FCF Trend:SELLSector/Industry Macro:BULLISHValuation Models:-


 


Technical AnalysisST Trend:UPMT Trend:UPLT Trend:UP




OctaFinance Rating*:NEUTRAL


* Read How Our Stock Ratings System Works








 Our experts have no choice but to rate the stock NEUTRAL, despite Isaac’s stock deal, because of our back-tested equities time momentum model which is displayed below. In the last 175 days alone the Atara Biotherapeutics Inc’s share price has climbed 113.06% and continues to smoothly trend up.
Price Chart of Atara Biotherapeutics NASDAQ:ATRA Stock
 
Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations
Hedge Funds Ownership
 Data gathered from SEC filings, reveal that 38 institutional players owned shares of Atara Biotherapeutics Inc. Octafinance tracked institutional players have traditionally had a low interest in this company, and that was also the case in Q4 2014. The institutional ownership was 47.18% of the stock’s outstanding shares.

 Ecor1 Capital Llc had the greatest investment with ownership of 385,124 shares as of Q4 2014 for 5.13% of the fund’s portfolio. Seth Klarman’s Baupost Group Llc Ma is another bullish institutional manager owning 2.50 million shares of the company or 1.16% of their stocks portfolio. The stock is also 0.2% of the fund’s AUM. The New York-based fund Bridger Management Llc have 0.41% of their stock portfolio invested in the stock for 243,450 shares. Further, The California-based fund Redmile Group Llc revealed it had purchased a stake worth 0.77% of the fund’s stock portfolio in the company. Jacob Gottlieb’s Visium Asset Management Lp was also a notable believer in the public company, owning 690,148 shares. Atara Biotherapeutics Inc is 0.26% of the fund’s stock portfolio.
Atara Biotherapeutics NASDAQ:ATRA Company Profile
Atara Biotherapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs with an initial focus on muscle wasting conditions and oncology. The Company’s lead product candidate, PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction, thereby blocking the negative regulation of skeletal muscle growth. PINTA 745 is in a Phase II clinical trial. The Company’s second product candidate, STM 434, which is in a Phase I clinical study, is a soluble ActR2B receptor that binds Activin A. The Company has five additional product candidates: ATA 842, a humanized antibody targeting myostatin; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-ActR2A/2B monoclonal antibody; STM 217, a soluble ActR2B receptor-IgG Fc fusion protein and a close analog of STM 434, and ActR2B5, a soluble ActR2B receptor that can be fused to an IgG Fc receptor.
Company Website: Atara Biotherapeutics
 Atara Biotherapeutics Inc was founded in Delaware on 2012-08-22. As of writing its market worth is: $1.39 billion and it has 24.76 million shares outstanding. Now the company has 40.16% shareholders and the institutional ownership is 40.16%. Atara Biotherapeutics Inc has 18 employees. The stock closed at $56.139999 yesterday and it had average 2 days volume of 120736 shares. It is up from the 30 days average shares volume of 107595. Atara Biotherapeutics Inc has a 52w low of $9.66 and a one year high of $199999.99. The current price is above the 200 days Simple moving average. Atara Biotherapeutics Inc last issued its quarterly earnings data on 05/07/2015. The company reported -0.42 EPS for the quarter, missing the consensus estimate of -0.36 by 0.06. The company had a revenue of for 3/31/2015 and for 12/31/2014. Therefore, the revenue was down.
* Transaction pursuant to Rule 10b5-1 Plan adopted December 12 – 2014.
* The price in Column 4 is a weighted average sale price. The prices actually received ranged from $55.58 to $56.55. The reporting person will provide to the issuer – any security holder of the issuer – or the SEC staff – upon request – information regarding the number of shares sold at each price within the range.
* Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08 – of which the Reporting Person is a trustee.
* The price in Column 4 is a weighted average sale price. The prices actually received ranged from $57.02 to $57.23. The reporting person will provide to the issuer – any security holder of the issuer – or the SEC staff – upon request – information regarding the number of shares sold at each price within the range.
* The price in Column 4 is a weighted average sale price. The prices actually received ranged from $54.73 to $55.73. The reporting person will provide to the issuer – any security holder of the issuer – or the SEC staff – upon request – information regarding the number of shares sold at each price within the range.
* The price in Column 4 is a weighted average sale price. The prices actually received ranged from $55.94 to $56.83. The reporting person will provide to the issuer – any security holder of the issuer – or the SEC staff – upon request – information regarding the number of shares sold at each price within the range.
* The price in Column 4 is a weighted average sale price. The prices actually received ranged from $56.96 to $57.87. The reporting person will provide to the issuer – any security holder of the issuer – or the SEC staff – upon request – information regarding the number of shares sold at each price within the range.
* Sheld are held by the Ciechanover Family GRAT – of which the Reporting Person is a trustee.
* Sheld are held by the The Ciechanover 2015 GRAT – of which the Reporting Person is a trustee.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.







 
Tagged: Atara Biotherapeutics - (NASDAQ:ATRA)Isaac Ciechanover



Daniel Hendrix, Interface, Inc. (NASDAQ:TILE)’s insider Sold 32,500 Shares Hanover Insurance Group Inc (NYSE:THG) Senior Vice President Mark Welzenbach, Unloaded $811,191 in Stock 



 





Free Email Newsletter
    Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:







Hedge Fund NewsTop 10 CITADEL ADVISORS 13F Holdings in Q3 2015DF DENT & CO INC Just Released Its Q3 2015 Stock PositionsMAVERICK CAPITAL Top 10 Holdings in Q3 2015Analyzing Ken Griffins CITADEL ADVISORS Stock Holdings in Q3 2015LONE PINE CAPITAL Top 10 13F Positions in Q3 2015Guru NewsFelix Zulauf Sees a Stock Market Correction Coming. This Rally S&P 500 (INDEXSP:.INX) Will Be Short-LivedMarc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and GoldJim Grant: The Next Thing Might Be Helicopter Money. What to Buy and Where He Sees Investment OpportunitiesKyle Bass Bearish on Emerging Markets for at least 2 More Years. Looking to Short CurrenciesDavid Tepper Gets Defensive. Is it Time to Get Out of The Stock Market?


Macro NewsChina Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking CrisisAre US – Russian Relations A Zero-Sum Game?US and Russia have launched direct talks on the conflict in SyriaYuan Drops as PBOC Cuts Reference Rate by Most Since DevaluationCould the market crash like 1987?—put volume spike argues low is nearCTAs NewsRed Rock Just Published Report About The Trend Following Landscape & How CTAs’ Performance Must Be AnalyzedHow to Implement Dual Momentum for non-US InvestorsDo Commodity Trading Advisors (CTAs) Really Provide Crisis Alpha, Equity Hedge and Are Long Volatility?



















 






Isaac Ciechanover, President & CEO, Atara Biotherapeutics


























&timesJavascript is disabled
























Market Profiles



Login
Sign up



Login


Sign up








 







 Edit

Person













Isaac Ciechanover



President & CEO
at
Atara Biotherapeutics


Location: San Diego, CA





Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop









Isaac Ciechanover



President & CEO
at
Atara Biotherapeutics


Location: San Diego, CA




Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop




Dr. Isaac Ciechanover is a physician, investor and entrepreneur driven by a passion to improve the practice of medicine. Motivated by the belief that the majority of medical discoveries still lie ahead, he has dedicated the past 20 years to working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He founded Atara Biotherapeutics in October 2012. Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield & Byers. Earlier as Celgene’s Executive Director in Business Development, he spearheaded the company’s venture capital efforts and led licensing and M&A activities with an aggregate value of more than $6.7 billion. Also at Celgene, he was Global Project Leader for the company’s first clinical-stage biologic therapy. Isaac has also held business development and venture capital roles at Amylin Pharmaceuticals, Pequot Ventures’ healthcare practice and Pfizer.



3

Companies in Career





N/A

Related Markets





4

Colleagues





N/A

Related Investments








Alias
N/A



Industry
R&D in Biotech, Environmental and various industries (no marketing product yet)




Tags
N/A




Topics of Influence












Web Site







N/A



























Careers








Achievements








Investments








Related People






 Edit
View all 



Isaac CiechanoverCareer (3)






Oct-2012




Atara Biotherapeutics



President & CEO












Celgene



Executive Director












Kleiner Perkins Caufield & Byers



Partner








Competencies










 Edit
View all 



Isaac CiechanoverEducation (4)










Cambridge University


M.Phil in Epidemiology










Weill Cornell Medical College













Harvard Business School













Stanford University


Psychology









 Edit



Isaac CiechanoverAchievements and Recognitions





Add Milestone


No milestones has been recorded for Isaac Ciechanover






 Edit



Isaac CiechanoverLinks





Add Link


No links has been recorded for Isaac Ciechanover









Isaac CiechanoverInvestments/Acquisitions





No investments has been recorded for Isaac Ciechanover









Isaac CiechanoverInvestments Representing Others





No investment reps has been recorded for Isaac Ciechanover








Isaac CiechanoverRelated People








Colleagues at Atara Biotherapeutics







Joe Newell

Executive Vice President and Chief Technical Operations Officer
Apr-2017









David Carmel

Head of Immunotherapy
Mar-2015









Derrell Porter

Senior Vice President and Global Commercial Head
Jul-2014









Gad Soffer

Chief Operating Officer
Mar-2013








View all 
Peers (77)







Joseph M. Hogan

President and CEO of Align Technology









Waleed Hassanein

President & CEO of TransMedics









Laura Brege

President & Chief Executive Officer of Nodality









Peter Maag

President and CEO of CareDx









Niamh Pellegrini

President & CEO of Autonomic Technologies









Jon P. Stonehouse

President, Chief Executive Officer of BioCryst Pharmaceuticals












View all 



Isaac CiechanoverRecommended Market Profiles (2)








Life Sciences (Kleiner Perkins Caufield & Byers)

10,000 or More employees
58 companies








Healthcare Corporate Venture Deals

2,500 - 5,000 employees
56 companies




















Isaac E. Ciechanover M.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 3:07 AM ET
Biotechnology

Company Overview of Atara Biotherapeutics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Isaac E. Ciechanover M.D.CEO, President & Director, Atara Biotherapeutics, Inc.AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 3 different industries.See Board Relationships46$10,014,420As of Fiscal Year 2016
Background

		Dr. Isaac E. Ciechanover, M.D., has been the President and Chief Executive Officer of Atara Biotherapeutics, Inc. since August 2012. Dr. Ciechanover serves as the President of Pinta Biotherapeutics, Inc. For more than 15 years, Dr. Ciechanover has worked with entrepreneurs and organizations to advance the practice of medicine through innovation and technology. With both a medical and business background, he bridges the gap between the scientific and business communities. ... He was an Investment Partner at Kleiner Perkins Caufield & Byers. He joined Kleiner, Perkins, Caufield & Byers in April 2010 and provided counsel and guidance to its network of life science entrepreneurs. Dr. Ciechanover was an Associate at FirstMark Capital, L.L.C. He served as the Executive Director of Business Development at Celgene Corporation. Dr. Ciechanover’s responsibilities included sourcing and execution and leading global teams for in-licensing and merger and acquisition activities for the research and development and commercial functions. He was also the Global Project Leader for Celgene Corporation’s first clinical stage biologic therapy and initiated and led its clinical, venture investment and alliance management activities. Dr. Ciechanover managed business development and planning for Amylin Pharmaceuticals. He also analyzed and vetted acquisition candidates at Pfizer Inc. He serves as a Director of Atara Biotherapeutics, Inc. and Pinta Biotherapeutics, Inc. Dr. Ciechanover drove life sciences venture capital efforts for Pequot Ventures. He began his career working as a venture capitalist in the healthcare practice of Pequot Ventures. He has sourced a number of investments for Pequot Ventures and is a board observer at Corventis, Crescendo, Elcelyx, Five Prime and Tesaro. Dr. Ciechanover is a contributor to the Multiple Myeloma Research Foundation and Project Smile. He received an M.D. from the Weill Cornell Medical College; an M.B.A. from the Harvard Business School; an M.Phil in Epidemiology from the University of Cambridge; and a B.A. in Psychology from Stanford University.Read Full Background




Corporate Headquarters
611 Gateway BoulevardSouth San Francisco, California 94080United StatesPhone: 650-278-8930Fax: --
Board Members Memberships
Member of the Board of the Directors and PresidentPinta Biotherapeutics, Inc.2012-PresentCEO, President & DirectorAtara Biotherapeutics, Inc.
Education
BA Stanford UniversityMBA Harvard Business SchoolMD Cornell UniversityMPH University of Cambridge
Other Affiliations
Kleiner Perkins Caufield & ByersFirstMark Capital, L.L.C.Stanford UniversityCelgene CorporationHarvard Business SchoolCornell UniversityUniversity of CambridgePinta Biotherapeutics, Inc.


Annual Compensation
Salary$546,000Bonus$327,870Total Annual Compensation$873,870
Stocks Options
Restricted Stock Awards$9,134,694All Other Compensation$5,856Exercisable Options$199,653Unexercisable Options$302,014Total Number of Options$501,667
Total Compensation
Total Annual Cash Compensation$879,726Total Short Term Compensation$873,870Other Long Term Compensation$9,140,550Total Calculated Compensation$10,014,420




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Atara Biotherapeutics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close


























    Isaac Ciechanover | Atara Biotherapeutics, Inc. | ZoomInfo.com



Ciechanover Isaac E. - SEC Form 4 Insider Trading Screener - OpenInsider











OpenInsider

Latest

Latest Cluster Buys
Latest Insider Trading (all filings)
Latest Insider Purchases
Latest Insider Purchases $25k+
Latest Officer Purchases $25k+
Latest CEO/CFO Purchases $25k+
Latest Insider Sales
Latest Insider Sales $100k+
Latest Officer Sales $100k+
Latest CEO/CFO Sales $100k+


Top

Top Officer Purchases Today
Top Officer Purchases Past Week
Top Officer Purchases Past Month
Top Insider Purchases Today
Top Insider Purchases Past Week
Top Insider Purchases Past Month
Top Insider Sales Today
Top Insider Sales Past Week
Top Insider Sales Past Month


By Symbol

Officer Purchases $25k+ Today
Officer Purchases $25k+ Past Week
Officer Purchases $25k+ Past Month
Officer Sales $100k+ Today
Officer Sales $200k+ Past Week
Officer Sales $500k+ Past Month
Officer Sales $100k+ Today (no opt-ex)
Officer Sales $200k+ Past Week (no opt-ex)
Officer Sales $500k+ Past Month (no opt-ex)
Insider Purchases of Penny Stocks, Past Month
Insider Sales of Penny Stocks, Past Month


Charts

Contact











Ciechanover Isaac E. - SEC Form 4 Insider Trading ScreenerCIK: 1612096 - Address: 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080 




General

Tickers
Insider
Sh Price $



Lqdty M$






Date

Filing Date

All dates
Custom
Latest day
Last 3 days
Last 1 week
Last 2 weeks
Last 1 month
Last 2 months
Last 3 months
Last 6 months
Last 1 year
Last 2 years
Last 4 years



  



Trade Date

All dates
Custom
Latest day
Last 3 days
Last 1 week
Last 2 weeks
Last 1 month
Last 2 months
Last 3 months
Last 6 months
Last 1 year
Last 2 years
Last 4 years



  


Filing Delay



N Days Ago








Transaction Filing

 P - Purchase S - Sale A - Grant D - Sale to Iss G - Gift F - Tax M - Option Ex X - Option Ex C - Cnv Deriv W - Inherited

 No deriv


 Multiple Days

Traded K$



Own Chg %








Industry




All Sectors (except Funds)
Agriculture, Forestry, Fish
Mining
Construction
Manufacturing
Transportation & Utilities
Wholesale Trade
Retail Trade
Financial
Services
Closed-End Funds


























Insider Title

  Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other






Group by


Filing
Company





Company Totals

Num Filings



Num Insiders



Num Officers



Traded K$



Own Chg %







Sort by

Filing Date
Trade Date
Ticker Symbol
Trade Value


Max Results
Page


clear


Real-time CSV, Options, Alerts








38 results -  -  -  -  -  -  - TCcnt1d1w1m6mS35-1-2-6-20 


X
Filing Date
Trade Date
Ticker
Insider NameInsider Title
Trade Type 
Share Price
Shares Traded
Shares Owned
Own chg
Value Traded
1d ret
1w ret
1m ret
6m ret



M2017-07-26 16:52:472017-07-24 ATRACiechanover Isaac E.CEOS - Sale$16.49-5,5001,182,4370%-$90,704
M2017-05-31 19:44:322017-05-30 ATRACiechanover Isaac E.CEOS - Sale$13.35-6,9001,187,937-1%-$92,115
M2017-05-19 16:05:372017-05-17 ATRACiechanover Isaac E.CEOS - Sale$14.91-4,8001,194,8370%-$71,568
M2017-04-26 19:34:102017-04-25 ATRACiechanover Isaac E.CEOS - Sale$17.56-7,2001,193,729-1%-$126,405-3-7
M2017-04-12 16:20:582017-04-10 ATRACiechanover Isaac E.CEOS - Sale$17.03-7,2001,200,929-1%-$122,598-1+6-13
M2017-03-28 20:13:532017-03-27 ATRACiechanover Isaac E.CEOS - Sale$20.06-16,0001,208,129-1%-$320,944+3+9-3
M2017-03-20 18:50:362017-03-16 ATRACiechanover Isaac E.CEOS - Sale$19.38-30,8001,224,129-2%-$596,808-5-3-15
DM2017-02-16 20:08:192017-02-15 ATRACiechanover Isaac E.CEOS - Sale+OE$15.55-4,8001,254,9290%-$74,6640-5+28
M2017-02-06 17:29:092017-02-02 ATRACiechanover Isaac E.CEOS - Sale$13.66-4,8001,088,8220%-$65,56800+13
M2017-01-19 16:34:412017-01-17 ATRACiechanover Isaac E.CEOS - Sale$14.24-6,0001,093,622-1%-$85,416-10+10
M2017-01-09 16:17:172017-01-05 ATRACiechanover Isaac E.CEOS - Sale$16.89-8,4001,099,622-1%-$141,864+1-10-8
M2016-12-23 18:52:222016-12-22 ATRACiechanover Isaac E.CEOS - Sale$15.22-4,8001,108,0220%-$73,073-3-10-11
M2016-12-08 17:16:372016-12-06 ATRACiechanover Isaac E.CEOS - Sale$17.93-7,2001,112,822-1%-$129,060+2-5-1
M2016-11-23 20:13:382016-11-22 ATRACiechanover Isaac E.CEOS - Sale$18.34-12,0001,120,022-1%-$220,106+2+2-27
M2016-10-28 20:37:102016-10-26 ATRACiechanover Isaac E.CEOS - Sale$13.80-4,8001,126,1140%-$66,264-6+5+46+24
M2016-10-17 16:27:512016-10-13 ATRACiechanover Isaac E.CEOS - Sale$15.96-4,8001,130,9140%-$76,608-2-8+29+13
M2016-09-29 16:26:412016-09-27 ATRACiechanover Isaac E.CEOS - Sale$20.87-12,0001,542,592-1%-$250,446+4-10-32-2
M2016-09-19 17:13:432016-09-15 ATRACiechanover Isaac E.CEOS - Sale$19.36-7,200827,714-1%-$139,356+6+5-16+11
M2016-08-23 19:57:582016-08-22 ATRACiechanover Isaac E.CEOS - Sale$22.33-9,600834,914-1%-$214,368-9-11-8-32
M2016-07-21 21:38:012016-07-20 ATRACiechanover Isaac E.CEOS - Sale$22.11-9,6001,169,563-1%-$212,208+1+8+2-37
M2016-07-11 16:42:092016-07-07 ATRACiechanover Isaac E.CEOS - Sale$22.88-9,6001,179,163-1%-$219,648-1-3-1-25
M2016-06-27 16:57:492016-06-23 ATRACiechanover Isaac E.CEOS - Sale$21.25-9,6001,188,763-1%-$204,048+7+9+10-29
M2016-06-08 20:19:572016-06-07 ATRACiechanover Isaac E.CEOS - Sale$20.53-12,0001,198,363-1%-$246,372-3-6+11-6
M2016-05-27 18:38:212016-05-25 ATRACiechanover Isaac E.CEOS - Sale$17.69-7,2001,210,363-1%-$127,368+3+4+19+11
M2016-04-26 21:17:282016-04-25 ATRACiechanover Isaac E.CEOS - Sale$20.12-1,3001,211,6560%-$26,159-2-5-5-20
M2016-04-13 19:49:542016-04-11 ATRACiechanover Isaac E.CEOS - Sale$20.40-13,2101,212,956-1%-$269,4840-3-26-13
M2016-04-04 16:48:192016-03-31 ATRACiechanover Isaac E.CEOS - Sale$20.03-1,1901,226,1660%-$23,839-40-140
M2016-01-15 16:06:582016-01-13 ATRACiechanover Isaac E.CEOS - Sale$20.20-2,4001,057,4750%-$48,468-12-10-24+5
M2016-01-04 16:11:142015-12-30 ATRACiechanover Isaac E.CEOS - Sale$26.00-2,4001,059,8750%-$62,388+4-8-23-5
M2015-12-16 17:10:532015-12-14 ATRACiechanover Isaac E.CEOS - Sale$22.46-2,4001,062,2750%-$53,908-3+1-11-12
M2015-12-07 17:15:502015-12-03 ATRACiechanover Isaac E.CEOS - Sale$37.45-4,0001,064,6750%-$149,780+2-2-26-34
M2015-11-25 16:04:142015-11-23 ATRACiechanover Isaac E.CEOS - Sale$35.03-4,8001,068,6750%-$168,163+3-3-40-57
M2015-10-23 19:26:462015-10-21 ATRACiechanover Isaac E.CEOS - Sale$25.85-3,2001,067,5670%-$82,726-1+6+39-15
M2015-10-08 16:21:552015-10-06 ATRACiechanover Isaac E.CEOS - Sale$33.08-4,0001,070,7670%-$132,336+1-8-3-31
M2015-09-25 18:49:312015-09-23 ATRACiechanover Isaac E.CEOS - Sale$42.99-5,2001,074,7670%-$223,531-12-24-37-53
M2015-09-14 18:59:552015-09-10 ATRACiechanover Isaac E.CEOS - Sale$46.16-5,2001,487,6780%-$240,045+2+9-24-57
M2015-08-31 18:52:572015-08-27 ATRACiechanover Isaac E.CEOS - Sale$39.25-5,2001,085,1670%-$204,086-4+4-18-57
M2015-08-03 17:16:112015-07-30 ATRACiechanover Isaac E.CEOS - Sale$56.18-5,2001,084,4600%-$292,1600-9-29-67
Real-time CSV? Options? Alerts? Contact us!



AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price


S - SaleSale of securities on an exchange or to another personS - Sale+OESale of securities on an exchange or to another person (after option exercise)F - TaxPayment of exercise price or tax liability using portion of securities received from the companyP - PurchasePurchase of securities on an exchange or from another person 

Return to top
Copyright © 2017 openinsider.com. All rights reserved.















Insider Trading - Ciechanover Isaac E. - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Ciechanover Isaac E.





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In


Goto page 0,
1,
Next
Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2016-12-22Sale
2016-12-236:52 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
4,800
$15.22
$73,073
555,044(DirectIndirect)
View


2016-12-06Sale
2016-12-085:16 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
7,200
$17.92
$129,060
555,044(DirectIndirect)
View


2016-11-22Sale
2016-11-238:13 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
12,000
$18.34
$220,106
555,044(DirectIndirect)
View


2016-10-26Sale
2016-10-288:37 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
4,800
$13.8
$66,264
549,136(DirectIndirect)
View


2016-10-13Sale
2016-10-174:27 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
4,800
$15.96
$76,608
549,136(DirectIndirect)
View


2016-09-27Sale
2016-09-294:26 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
12,000
$20.87
$250,446
549,136(DirectIndirect)
View


2016-09-15Sale
2016-09-195:13 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
7,200
$19.35
$139,356
422,178(DirectIndirect)
View


2016-08-22Sale
2016-08-237:57 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
9,600
$22.33
$214,368
430,578(DirectIndirect)
View


2016-07-20Sale
2016-07-219:38 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
9,600
$22.1
$212,208
450,824(DirectIndirect)
View


2016-07-07Sale
2016-07-114:42 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
9,600
$22.88
$219,648
450,824(DirectIndirect)
View


2016-06-23Sale
2016-06-274:57 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
9,600
$21.26
$204,048
450,824(DirectIndirect)
View


2016-06-07Sale
2016-06-088:19 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
12,000
$20.53
$246,372
450,824(DirectIndirect)
View


2016-05-25Sale
2016-05-276:38 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
7,200
$17.69
$127,368
450,824(DirectIndirect)
View


2016-04-25Sale
2016-04-269:17 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
1,300
$20.12
$26,159
450,824(IndirectDirect)
View


2016-04-11Sale
2016-04-137:49 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
13,210
$20.4
$269,484
450,824(IndirectDirect)
View


2016-03-31Sale
2016-04-044:48 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
1,190
$20.03
$23,839
450,824(IndirectDirect)
View


2016-01-13Sale
2016-01-154:06 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
2,400
$20.19
$48,468
450,824(IndirectDirect)
View


2015-12-30Sale
2016-01-044:11 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
2,400
$25.99
$62,388
450,824(IndirectDirect)
View


2015-12-14Sale
2015-12-165:10 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
2,400
$22.46
$53,908
450,824(IndirectDirect)
View


2015-12-03Sale
2015-12-075:15 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
4,000
$37.45
$149,780
450,824(IndirectDirect)
View


2015-11-23Sale
2015-11-254:04 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
4,800
$35.03
$168,163
450,824(IndirectDirect)
View


2015-10-21Sale
2015-10-237:26 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
3,200
$25.85
$82,726
450,824(IndirectDirect)
View


2015-10-06Sale
2015-10-084:21 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
4,000
$33.08
$132,336
450,824(IndirectDirect)
View


2015-09-23Sale
2015-09-256:49 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,200
$42.99
$223,531
450,824(IndirectDirect)
View


2015-09-10Sale
2015-09-146:59 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,200
$46.16
$240,045
450,824(IndirectDirect)
View


2015-08-27Sale
2015-08-316:52 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,200
$39.25
$204,086
488,653(IndirectDirect)
View


2015-07-30Sale
2015-08-035:16 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,200
$56.18
$292,160
488,653(IndirectDirect)
View


2015-07-16Sale
2015-07-208:30 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,200
$60.71
$315,680
488,653(IndirectDirect)
View


2015-06-30Sale
2015-07-026:16 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,200
$50.42
$262,160
488,653(IndirectDirect)
View


2015-06-17Sale
2015-06-197:25 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,200
$54.72
$284,545
488,653(IndirectDirect)
View


2015-06-04Sale
2015-06-086:42 pm
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
6,400
$42.91
$274,596
488,653(IndirectDirect)
View




Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-11-15Exercise
2016-11-174:54 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,908
$0
555,044(Direct)
View


2016-11-15Exercise
2016-11-174:54 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,908
$0
555,044(Direct)
View


2016-09-22Option Award
2016-09-237:25 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
320,000
$0
549,136(Direct)
View


2016-08-15Exercise
2016-08-177:43 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,908
$0
435,378(Direct)
View


2016-08-15Gift
2016-08-177:43 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
330,957
$0
435,378(Indirect)
View


2016-08-15Exercise
2016-08-177:43 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,908
$0
435,378(Direct)
View


2016-05-16Exercise
2016-05-187:02 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,907
$0
450,824(Direct)
View


2016-05-16Exercise
2016-05-187:02 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,907
$0
450,824(Direct)
View


2016-02-16Exercise
2016-02-188:12 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,908
$0
450,824(Direct)
View


2016-02-16Exercise
2016-02-188:12 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,908
$0
450,824(Direct)
View


2016-02-09Option Award
2016-02-118:48 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
163,973
$0
450,824(Indirect)
View


2015-12-17Option Award
2015-12-215:07 pm
N/A2022-12-17
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
220,000
$22.72
220,000(Direct)
View


2015-11-16Exercise
2015-11-186:52 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,908
$0
450,824(Direct)
View


2015-11-16Exercise
2015-11-186:52 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,908
$0
450,824(Direct)
View


2015-08-17Exercise
2015-08-198:25 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,907
$0
488,653(Direct)
View


2015-08-17Exercise
2015-08-198:25 pm
N/AN/A
Atara Biotherapeutics Inc.
ATRA
Ciechanover Isaac E.Chief Executive OfficerDirector
5,907
$0
488,653(Direct)
View





Goto page 0,
1,
Next





    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 02:07:09 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  








